Publications

5674 Results

Impact of value of information analyses on SWOG’s clinical trial capsule scoring

Authors
JJ Carlson;D Kim;G Guzauskas;C Bennette;DL Hershman;L Baker;N Hendrix;A Basu;DL Veenstra;S Ramsey
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr e18311); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017Chicago, IL), publish only
Year
2017
Research Committee(s)
Cancer Care Delivery

National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers

Authors
A Denicoff;G Mishkin;M Good;L Patrichuk;L Ragard;KR Hurtado;K Willenberg;C Szczepanek;C Dawson;M Alexander-Young;D Stranberg;J Kardell;S McCartney;MB Sullivan;M Kelly;MJ Montello;W McCaskill-Stevens;J Abrams;M Mooney
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 6542); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Cancer Care Delivery

The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials

Authors
J Unger;W Barlow;C Tangen;S Ramsey;IM Thompson;EA Klein;M Leblanc;C Blanke;P Goodman;L Minasian;D Hershman
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 1541); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
Study Number(s)
S0000, SWOG-9217

The impact of positive SWOG treatment trials on population survival

Authors
J Unger;M LeBlanc;C Blanke
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Multiple sites, and Myeloma
Study Number(s)
S0226, S0777, SWOG-7436, SWOG-7704/05, SWOG-7817, SWOG-8494 (INT-0036), SWOG-8501 (INT-0051), SWOG-8591(NCI Intergroup #0035), SWOG-8624, SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891), SWOG-8736 (INT-0093), SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12), SWOG-8814, SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817), SWOG-8897, SWOG-8949, SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195), SWOG-9126, SWOG-9210, SWOG-9308, S9916

A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 (Excision Repair Cross-Complementing 1) for advanced/ metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer: SWOG S1201

Authors
S Iqbal;S McDonough;H Lenz;D Ilson;B Burtness;CS Nangia;A Barzi;CJ Schneider;J Liu;E Dotan;K Guthrie;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4009); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1201

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;SM Stein;V Sahai;GP Keogh;EJ Kim;AD Baron;AB Siegel;A Barzi;K Guthrie;M Javle;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4016); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussioin
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Authors
ES Kopetz;S McDonough;H Lenz;A Magliocco;C Atreya;L Diaz;C Allegra;K Raghav;VK Morris;S Wang;C Lieu;K Guthrie;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3505); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1406

Randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513

Authors
EG Chiorean;S McDonough;PA Philip;E Swisher;M Pishvaian;K Guthrie;A Lowy;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4147); American Society of Clinical Oncology (ASCO) Annual Meeting(June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1513

Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials

Authors
A Barzi;D Hershman;C Till;H Lenz;H Hochster;W Barlow;J Unger
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 10056); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9304 (INT-0144), SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415), SWOG-9420

Primary tumor location is an independent prognostic maker from CMS and MSI for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Authors
A Venook;FS Ou;F Innocenti;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;H Lenz
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3503); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405